FILTER
LATEST ARTICLES
The Battery Material Supply Chain
February 15, 2022
How the mining sector will play a pivotal role in determining the world's climate change and green revolution outcomes.
Industry Thoughts on Battery Metals
February 15, 2022
Ontario’s battery metal juniors share their opinions.
Logistics Challenges in 2021
August 27, 2021
How logistics specialists are dealing with global supply chain disruptions that have no near-term solution.
Industry Thoughts on Latin American Logistics
August 27, 2021
International logistics providers have their say on supply chain disruptions.
Sustainability in Mining
August 06, 2021
More than a buzzword, ESG has become the overarching theme impacting all facets of mining.
Funding Environment: Life Sciences Enter the Mainstream
April 20, 2021
The past 12 months been transformative for the life science industry in USA, and GBR explores how the funding environment has evolved to provide the influx of capital to sustain its innovations.
The Global Tailings Standard
April 16, 2021
The mining industry and investment community are collaborating to mitigate a perpetual risk, after a series of high-profile disasters.
Tailings Management
April 16, 2021
Expert Opinion Article by Dan Etheredge, General Manager, Klohn Crippen Berger S.A.
Optimism Returns to Peru’s Mining Sector
March 21, 2021
Surging copper brings renewed optimism to Peru, but a pivotal election looms.
Canada, Light at the End of the Tunnel
February 05, 2021
Rising metals prices and industry resilience have helped miners weather the storm.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
